Richard J Epstein

Summary

Affiliation: The University of Hong Kong
Country: China

Publications

  1. pmc Learning from the problems of problem-based learning
    Richard J Epstein
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    BMC Med Educ 4:1. 2004
  2. pmc A structural split in the human genome
    Clara S M Tang
    Laboratory of Computational Oncology, Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong, Hong Kong
    PLoS ONE 2:e603. 2007
  3. doi The threat that dare not speak its name: human extinction
    R J Epstein
    Laboratory of Computational Oncology, Department of Medicine, University of Hong Kong, Professorial Block, Queen Mary Hospital, Hong Kong, USA
    Perspect Biol Med 52:116-25. 2009
  4. ncbi Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Hong Kong
    Cancer Invest 24:367-73. 2006
  5. ncbi Reversing hepatocellular carcinoma progression by using networked biological therapies
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, China
    Clin Cancer Res 13:11-7. 2007
  6. pmc Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of care
    Richard J Epstein
    Division of Haematology Oncology, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    BMC Cancer 7:92. 2007
  7. ncbi VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    Cancer Metastasis Rev 26:443-52. 2007
  8. ncbi Growth of the Asian health-care market: global implications for the pharmaceutical industry
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    Nat Rev Drug Discov 6:785-92. 2007
  9. doi Loading doses for costly cancer biologicals: sound pharmacology or unnecessary extravagance?
    Richard J Epstein
    Division of Haematology Oncology, Room 802, Administrative Block, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong
    Eur J Cancer 44:1488-92. 2008
  10. doi Tumor resensitization to erlotinib following brief substitution of cetuximab
    R J Epstein
    Division of Haematology and Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Room 802, Administration Block, Pokfulam, Hong Kong, China
    Cancer Chemother Pharmacol 62:1111-2. 2008

Collaborators

Detail Information

Publications38

  1. pmc Learning from the problems of problem-based learning
    Richard J Epstein
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    BMC Med Educ 4:1. 2004
    ..This paradigm shift has been justified by studies showing that PBL improves reasoning and communication while being associated with few if any detectable knowledge deficits...
  2. pmc A structural split in the human genome
    Clara S M Tang
    Laboratory of Computational Oncology, Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong, Hong Kong
    PLoS ONE 2:e603. 2007
    ..To address this paradox, we used data mining to assess the behavior of PCI-positive (PCI+) genes in the human genome...
  3. doi The threat that dare not speak its name: human extinction
    R J Epstein
    Laboratory of Computational Oncology, Department of Medicine, University of Hong Kong, Professorial Block, Queen Mary Hospital, Hong Kong, USA
    Perspect Biol Med 52:116-25. 2009
    ....
  4. ncbi Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Hong Kong
    Cancer Invest 24:367-73. 2006
    ..Here, we describe our experience using a web-based program to support adjuvant decision making at a multidisciplinary breast cancer Tumor Board in a university-affiliated oncology center...
  5. ncbi Reversing hepatocellular carcinoma progression by using networked biological therapies
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, China
    Clin Cancer Res 13:11-7. 2007
    ..Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials...
  6. pmc Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of care
    Richard J Epstein
    Division of Haematology Oncology, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    BMC Cancer 7:92. 2007
    ..To assess the evidence for this radical change in thinking, a review of relevant studies in the fields of breast cancer chemotherapy, pregnancy, and drug safety was conducted...
  7. ncbi VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    Cancer Metastasis Rev 26:443-52. 2007
    ..The emerging model of anti-VEGF drug action being mediated primarily by tumoral (as distinct from endothelial) VEGFRs has clinically important implications for optimizing the anti-metastatic efficacy of this expanding drug class...
  8. ncbi Growth of the Asian health-care market: global implications for the pharmaceutical industry
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    Nat Rev Drug Discov 6:785-92. 2007
    ..Success in meeting these challenges will go to those pharmaceutical companies that best understand the unique strengths and constraints of Asia's diverse cultures, talents and markets...
  9. doi Loading doses for costly cancer biologicals: sound pharmacology or unnecessary extravagance?
    Richard J Epstein
    Division of Haematology Oncology, Room 802, Administrative Block, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong
    Eur J Cancer 44:1488-92. 2008
    ....
  10. doi Tumor resensitization to erlotinib following brief substitution of cetuximab
    R J Epstein
    Division of Haematology and Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Room 802, Administration Block, Pokfulam, Hong Kong, China
    Cancer Chemother Pharmacol 62:1111-2. 2008
    ..Here, we describe a case of pancreatic cancer in which the small-molecule EGFR antagonist erlotinib was used before and after the EGFR antibody cetuximab, with unexpected potentiation of both toxic and therapeutic sequelae...
  11. pmc "Leaving town" versus "taking leave": the case for re-thinking academic leave restrictions
    R J Epstein
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong
    Postgrad Med J 81:732-3. 2005
  12. ncbi Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment
    Richard J Epstein
    Department of Medicine, University of Hong Kong, Professorial Block, Queen Mary Hospital, Pokfulam, Hong Kong
    Clin Cancer Res 11:5337-41. 2005
    ..The traditional view of cytoreductive response as a prerequisite for adjuvant drug efficacy thus merits reappraisal, with a view to accelerating incorporation of novel noncytotoxic maintenance therapies into controlled studies...
  13. doi TNM: therapeutically not mandatory
    Richard J Epstein
    Division of Haematology Oncology, Department of Medicine, The University of Hong Kong, 4 F Professorial Block, Queen Mary Hospital, Pokfulam, Hong Kong
    Eur J Cancer 45:1111-6. 2009
    ..To these ends, a modernised decision-oriented disease staging system called METS (molecular/extra-primary/tumour/symptoms) is presented here...
  14. ncbi Journal impact factors do not equitably reflect academic staff performance in different medical subspecialties
    Richard J Epstein
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
    J Investig Med 52:531-6. 2004
    ..The present study tests the hypotheses that IFs exhibit patterns that are consistent between journals of different specialties and that these IFs reflect the quality of staff academic performance...
  15. ncbi The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies
    Richard J Epstein
    Department of Medicine, The University of Hong Kong, Room 404, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong
    Nat Rev Cancer 4:901-9. 2004
    ....
  16. doi Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors
    Richard J Epstein
    Medical Oncology Unit, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    Clin Breast Cancer 9:184-6. 2009
    ..Prompt ophthalmoscopic evaluation is thus recommended for any patient who is prescribed treatment with an aromatase inhibitor and subsequently develops visual symptoms...
  17. doi Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic disease
    Thomas Yau
    Division of Haematology Oncology, University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong
    Clin Colorectal Cancer 9:108-12. 2010
    ..Although CEA levels have been reported to rise during adjuvant drug therapies, the mechanism of such 'surges' is not clear. This study was conducted to clarify the clinical significance of this phenomenon...
  18. ncbi Intron length and accelerated 3' gene evolution
    Clara S Tang
    Laboratory of Computational Oncology, Department of Medicine, Pokfulam, Hong Kong
    Genomics 88:682-9. 2006
    ..0003). We conclude that the efficiency of transcription-coupled repair decreases with gene length, suggesting in turn that 3' gene evolution is accelerated both by introns and by gene methylation...
  19. pmc Programmed genetic instability: a tumor-permissive mechanism for maintaining the evolvability of higher species through methylation-dependent mutation of DNA repair genes in the male germ line
    Yongzhong Zhao
    Laboratory of Computational Oncology, Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
    Mol Biol Evol 25:1737-49. 2008
    ....
  20. pmc PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success
    Hilda Wong
    Division of Hematology Oncology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
    Pathol Oncol Res 16:87-91. 2010
    ..We propose diagnostic criteria for this under-recognized new clinical syndrome, and recommend that physicians routinely measure serum gastrin levels in persistent cases of PPI-dependent dyspepsia unassociated with H. pylori...
  21. ncbi Clinicopathological correlates in a cohort of Hong Kong breast cancer patients presenting with screen-detected or symptomatic disease
    Amy W Leung
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    Hong Kong Med J 13:194-8. 2007
    ..To examine the differences in breast cancer presentation by analysing our recent experience in the diagnosis and management of breast cancer patients...
  22. ncbi Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma
    Thomas Yau
    Department of Medicine, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong, China
    Oncology 72:67-71. 2007
    ..Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action. We aim to evaluate the efficacy and toxicity of low-dose (100 mg) thalidomide as the first-line treatment of advanced HCC...
  23. doi Evidence for a programming effect of early menarche on the rise of breast cancer incidence in Hong Kong
    Amy W H Leung
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China
    Cancer Detect Prev 32:156-61. 2008
    ....
  24. ncbi Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis
    Joanne Chiu
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China E mail
    Asian Pac J Cancer Prev 14:6585-90. 2014
    ..Moreover, uncertainties persist as to whether pharmacogenetic differences in Asian populations preclude equally tolerable and effective administration of these drugs...
  25. doi Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status
    Jingbo Xiong
    Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, SAR China
    Mol Cancer Ther 8:779-85. 2009
    ....
  26. ncbi Multidisciplinary approach to the management of breast cancer in Hong Kong
    Wai Fan Chan
    Department of Surgery, University of Hong Kong Medical Centre, Hong Kong, China
    World J Surg 30:2095-100. 2006
    ..The present study reviews the applicability of the multidisciplinary approach to the management of patients with breast cancer in a private hospital...
  27. doi Complications of traditional Chinese/herbal medicines (TCM)--a guide for perplexed oncologists and other cancer caregivers
    Joanne Chiu
    Division of Hematology Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd, Pokfulam, Hong Kong
    Support Care Cancer 17:231-40. 2009
    ..If unrecognized, these problems may be misattributed to conventional treatment toxicity or disease progression, and remedial action may be inappropriate or delayed...
  28. pmc Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy
    Hilda Wong
    Division of Hematology Oncology, University Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
    BMC Cancer 14:826. 2014
    ..Here we address this discrepancy by comparing early-stage ILC and IDC in two breast cancer patient cohorts of differing nationality and ethnicity...
  29. ncbi Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy
    Richard J Epstein
    Division of Haematology Oncology, Department of Medicine, University of Hong Kong, Room 404, Professorial Block, Queen Mary Hospital, Pokfulam Rd, Pokfulam, Hong Kong
    Cancer Chemother Pharmacol 58:835-7. 2006
    ..Here, we report a case of fulminant panmucositis complicating dose-dense adjuvant breast cancer treatment in a betel-chewing patient without evidence of other risk factors...
  30. doi Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy
    Thomas Yau
    Department of Medicine, University of Hong Kong Medical Centre, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China
    Ann Surg Oncol 15:2500-5. 2008
    ....
  31. pmc Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer
    H Wong
    Division of Haematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Br J Cancer 102:1391-6. 2010
    ..To clarify whether concomitant DCIS affects IDC prognosis, we compared Ki-67 expression and node status of size-matched IDC subgroups either with DCIS (IDC-DCIS) or without DCIS (pure IDC)...
  32. ncbi Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs
    Yoon Pin Lim
    Division of Medical Sciences and Department of Surgical Oncology, National Cancer Centre, Singapore
    Clin Cancer Res 10:3980-7. 2004
    ..To clarify this discrepancy, we compared the patterns of tyrosine phosphoprotein expression in human cancer cells and primary tumors...
  33. pmc Breast self examination. Breast self examination provides entry strategy
    Richard J Epstein
    BMJ 326:710. 2003
  34. ncbi Quick-FLIC--a short questionnaire for assessing quality of life of cancer patients
    Yin Bun Cheung
    Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore
    Acta Oncol 42:36-42. 2003
    ..It is concluded that the shortening of established health-related quality of life instruments is viable in oncology research...
  35. ncbi Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ
    Thomas Yau
    Lancet 362:1154-5; author reply 1155-6. 2003
  36. ncbi Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells
    Yoon Pin Lim
    Laboratory of Tumor Phosphoproteomics, Division of Medical Sciences, National Cancer Centre, Singapore
    Mol Cancer Ther 2:1369-77. 2003
    ....
  37. ncbi Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention
    Kok Long Ang
    Laboratory of Tumor Phosphoproteomics, National Cancer Centre, Singapore
    Cancer Lett 225:53-9. 2005
    ..Moreover, since recent reports confirm Akt inhibition by COX-2 inhibitors, these data support the chemopreventive efficacy of such drugs for at-risk individuals...
  38. ncbi Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
    Dongsheng Chen
    Department of Cancer Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Oncogene 21:4921-31. 2002
    ..Finally, we show that ERalpha is phosphorylated at S118 in vivo using immunoblotting of extracts prepared from a series of ERalpha-positive breast tumours...